Effect of Nitric Oxide (NO) on Ischemic/Reperfusion Injury During Extended Donor Criteria (EDC) Liver Transplantation
Primary Purpose
Liver Transplantation, Ischemia/Reperfusion Injury, Oxidative Injury
Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Nitric Oxide
Sponsored by
About this trial
This is an interventional treatment trial for Liver Transplantation focused on measuring Extended Donor Criteria
Eligibility Criteria
Inclusion Criteria:
- Age 18 - 69 years of age
- moderate to severe liver disease (MELD score 22 to 30)
- is receiving a extended donor criteria liver graft
Exclusion Criteria:
- undergoing multi-organ transplant
- 70 years or older
- diagnosed with hepatocarcinoma
- diagnosed with either hepatopulmonary syndrome or pulmonary hypertension
- pregnant
Sites / Locations
- University of Colorado Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Experimental
Arm Label
No nitric oxide
Nitric Oxide
Arm Description
This arm will not receive nitric oxide, but will receive other standard inhaled anesthetics
Will receive Nitric oxide and other standard inhaled anesthetics
Outcomes
Primary Outcome Measures
To Determine if Inhaled Nitric Oxide Has Beneficial Effects on Overall Outcome After Extended Criteria Donor (EDC) Liver Transplantation
Secondary Outcome Measures
To Construct a Plasma Metabolic/Protein Profile of I/R Injury in Transplanted Livers
To Examine the Effects of Nitric Oxide on Protein Synthesis and Metabolism Following Extended Criteria Donor Liver Transplantation
Full Information
NCT ID
NCT00948194
First Posted
July 24, 2009
Last Updated
May 26, 2021
Sponsor
University of Colorado, Denver
1. Study Identification
Unique Protocol Identification Number
NCT00948194
Brief Title
Effect of Nitric Oxide (NO) on Ischemic/Reperfusion Injury During Extended Donor Criteria (EDC) Liver Transplantation
Official Title
Investigation of the Effect of Nitric Oxide on Ischemic Reperfusion Injury During Extended Donor Criteria Liver Transplantation
Study Type
Interventional
2. Study Status
Record Verification Date
May 2021
Overall Recruitment Status
Terminated
Why Stopped
This study was terminated when the P.I. left the university.
Study Start Date
October 2009 (undefined)
Primary Completion Date
December 2015 (Actual)
Study Completion Date
December 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Colorado, Denver
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
In this study, the researchers propose to investigate the efficacy of inhaled nitric oxide to prevent ischemia-reperfusion (I/R) hepatocyte injury in patients who receive extended donor criteria(EDC)liver grafts based on changes in proteomic and metabolomic markers following revascularization of the donor graft.
In reviewing the literature, no uniform extended criteria donor classification exists. The characteristics most associated with liver graft failure appear to be cold ischemia time greater than 10 hours, warm ischemia time greater than 40 minutes, donor age > 55 years of age, donor hospitalization > 5 days, a donation after cardiac death (DCD) graft, and a split graft. The researchers will exclude warm ischemia time as this is impossible to predict prior to the transplantation. Any donor meeting at least one of the other criteria will be classified as an EDC donor.
Hypothesis 1: Inhaled nitric oxide will improve overall outcome of liver recipients after EDC liver transplantation
Suppression of oxidative injury will improve graft function postoperatively as measured by International Normalized Ratio (INR) bilirubin, transaminases, and duration of hospital stay.
Hypothesis 2: The mechanisms of therapeutic efficacy of inhaled nitric oxide is based on reduction in post-reperfusion oxidative injury as readily measured by the detectable changes in the protein and metabolic profiles in plasma of patients treated with inhaled-NO
Nuclear Magnetic Resonance (NMR)-based metabolic markers (xanthine end-products, lactate, and hepatic osmolytes) that are consistent with acute liver injury will be decreased in NO-treated recipients.
Protein markers of reperfusion injury (argininosuccinate synthase (ASS) and estrogen sulfotransferase (EST-1) will be greater in the plasma of patients who are not treated with inhaled-NO
Reduced oxidative injury will be reflected by a decrease in the number of mitochondrial peroxiredoxins isoforms and the number that are oxidized in NO-treated liver recipients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Liver Transplantation, Ischemia/Reperfusion Injury, Oxidative Injury
Keywords
Extended Donor Criteria
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
13 (Actual)
8. Arms, Groups, and Interventions
Arm Title
No nitric oxide
Arm Type
No Intervention
Arm Description
This arm will not receive nitric oxide, but will receive other standard inhaled anesthetics
Arm Title
Nitric Oxide
Arm Type
Experimental
Arm Description
Will receive Nitric oxide and other standard inhaled anesthetics
Intervention Type
Drug
Intervention Name(s)
Nitric Oxide
Other Intervention Name(s)
INOmax
Intervention Description
Inhalation - 40 ppm, at the initiation of anesthesia to the end of surgery
Primary Outcome Measure Information:
Title
To Determine if Inhaled Nitric Oxide Has Beneficial Effects on Overall Outcome After Extended Criteria Donor (EDC) Liver Transplantation
Time Frame
3 years
Secondary Outcome Measure Information:
Title
To Construct a Plasma Metabolic/Protein Profile of I/R Injury in Transplanted Livers
Time Frame
3 years
Title
To Examine the Effects of Nitric Oxide on Protein Synthesis and Metabolism Following Extended Criteria Donor Liver Transplantation
Time Frame
3 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
69 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 18 - 69 years of age
moderate to severe liver disease (MELD score 22 to 30)
is receiving a extended donor criteria liver graft
Exclusion Criteria:
undergoing multi-organ transplant
70 years or older
diagnosed with hepatocarcinoma
diagnosed with either hepatopulmonary syndrome or pulmonary hypertension
pregnant
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Matthew J. Fiegel, M.D.
Organizational Affiliation
University of Colorado, Denver
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Colorado Hospital
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Effect of Nitric Oxide (NO) on Ischemic/Reperfusion Injury During Extended Donor Criteria (EDC) Liver Transplantation
We'll reach out to this number within 24 hrs